Impairment of maturation of BMP-6 (35kDa) correlates with delayed fracture healing in experimental diabetes
Background: Although it is known that diabetes interferes with fracture healing, the mechanisms remain poorly understood. The aim of this study was to investigate the correlation of BMP-6 and BMP-9 with the impairment in fracture healing in diabetes, by analyses of the difference in size and calcification of the callus, mechanical endurance and expressing BMP-6 and BMP-9 in the callus, using a clinical related diabetic rodent model.
Methods: We evaluated femur fracture healing by quantification of size and calcification of the callus by X-ray, histological and histochemical images, loading capacity of the fractured bone and amount of BMP-6 in the callus and the bones using Western blot assay.
Results: Significant upregulation of BMP-6 in the callus and the fractured bones of both non-diabetic and the diabetic animals was observed, at the end of the 2nd and the 4th weeks after fracture. However, significantly lower levels of BMP-6 at 35kDa with smaller sizes of calcified callus and poor loading capacity of the healing bones were detected in the diabetic animals, compared to the non-diabetic controls. The impairment of the maturation procedure of BMP-6 (35 kDa) from precursors may be underlying the downregulation of the BMP-6 in diabetic animals.
Conclusions: It could be concluded that the delayed fracture healing in the diabetic animals is correlated with deficiency of BMP-6 (35 kDa), which may be caused by impairment of maturation procedure of BMP-6 from precursors to functioning format. This is a primary study but an important step to explore the molecular pathogenesis of impairment of fracture healing in diabetes and to molecular therapeutic approach for the impairment of fracture healing.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Posted 16 Apr, 2020
Received 28 Apr, 2020
On 17 Apr, 2020
On 14 Apr, 2020
Invitations sent on 14 Apr, 2020
On 14 Apr, 2020
On 13 Apr, 2020
On 13 Apr, 2020
On 06 Apr, 2020
On 06 Apr, 2020
On 05 Apr, 2020
On 02 Apr, 2020
On 30 Mar, 2020
Impairment of maturation of BMP-6 (35kDa) correlates with delayed fracture healing in experimental diabetes
Posted 16 Apr, 2020
Received 28 Apr, 2020
On 17 Apr, 2020
On 14 Apr, 2020
Invitations sent on 14 Apr, 2020
On 14 Apr, 2020
On 13 Apr, 2020
On 13 Apr, 2020
On 06 Apr, 2020
On 06 Apr, 2020
On 05 Apr, 2020
On 02 Apr, 2020
On 30 Mar, 2020
Background: Although it is known that diabetes interferes with fracture healing, the mechanisms remain poorly understood. The aim of this study was to investigate the correlation of BMP-6 and BMP-9 with the impairment in fracture healing in diabetes, by analyses of the difference in size and calcification of the callus, mechanical endurance and expressing BMP-6 and BMP-9 in the callus, using a clinical related diabetic rodent model.
Methods: We evaluated femur fracture healing by quantification of size and calcification of the callus by X-ray, histological and histochemical images, loading capacity of the fractured bone and amount of BMP-6 in the callus and the bones using Western blot assay.
Results: Significant upregulation of BMP-6 in the callus and the fractured bones of both non-diabetic and the diabetic animals was observed, at the end of the 2nd and the 4th weeks after fracture. However, significantly lower levels of BMP-6 at 35kDa with smaller sizes of calcified callus and poor loading capacity of the healing bones were detected in the diabetic animals, compared to the non-diabetic controls. The impairment of the maturation procedure of BMP-6 (35 kDa) from precursors may be underlying the downregulation of the BMP-6 in diabetic animals.
Conclusions: It could be concluded that the delayed fracture healing in the diabetic animals is correlated with deficiency of BMP-6 (35 kDa), which may be caused by impairment of maturation procedure of BMP-6 from precursors to functioning format. This is a primary study but an important step to explore the molecular pathogenesis of impairment of fracture healing in diabetes and to molecular therapeutic approach for the impairment of fracture healing.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7